ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Impact of Induction Immunosuppression on Renal Recovery in Adult Liver Transplant Recipients – A Single Center Experience

T. Zurick1, D. Bruno2, D. Kumar3, R. Winstead1, C. Song1, A. Brown1, S. Sterling1, I. Yakubu1

1Pharmacy, VCU Health System, Richmond, VA, 2Transplant Surgery, VCU Health System, Richmond, VA, 3Transplant Nephrology, VCU Health System, Richmond, VA

Meeting: 2022 American Transplant Congress

Abstract number: 1089

Keywords: Induction therapy, Liver transplantation, Rejection, Renal dysfunction

Topic: Clinical Science » Liver » 54 - Liver: Immunosuppression and Rejection

Session Information

Session Name: Liver: Immunosuppression and Rejection

Session Type: Poster Abstract

Date: Sunday, June 5, 2022

Session Time: 7:00pm-8:00pm

 Presentation Time: 7:00pm-8:00pm

Location: Hynes Halls C & D

*Purpose: Renal dysfunction after liver transplantation (LT) is associated with increased morbidity and mortality. Early exposure to calcineurin inhibitors (CNI) is a risk factor for renal dysfunction after LT. Attempts to delay CNI introduction with the addition of induction immunosuppression (IS) in LT candidates with renal dysfunction have shown mixed results. Here, we report our experience with induction strategies versus no induction in the setting of delayed CNI initiation on renal function after LT.

*Methods: Between January 2016 and June 2021, we retrospectively reviewed outcomes of adult primary liver only transplant recipients (LTR) with renal impairment. Renal impairment was defined as the need for dialysis or SCr greater than or equal to 1.8 mg/dL at the time of LT or within 24-hours after LT. Patients meeting criteria received either induction with rabbit anti-thymocyte globulin (rATG) or basiliximab (Group 1) or no induction (Group 2). All patients received perioperative steroids and delayed CNI initiation. The primary outcome was the change in estimated glomerular filtration rate (eGFR) from baseline to 3-months post-LT.

*Results: A total of 79 LTR were included (38 in Group 1 and 41 in Group 2). Patients in Group 2 had a higher median MELD-Na score compared to those in Group 1, 40 vs. 29 (p < .001), were more likely to be on dialysis prior to transplant, 71% vs. 24% (p < .001), and had a lower mean baseline eGFR, 18.2 ± 8 mL/min/1.73m2 vs. 41.0 ± 30 mL/min/1.73m2 (p < .001), respectively. At 3 months, patients in Group 2 had a significant improvement in mean eGFR, 28.6 ± 27 mL/min/1.73m2, compared to those in Group 1, 8.8 ± 37 mL/min/1.73m2, (p = 0.007). BPAR rates within the first 30-days were 15% vs. 0% (p = 0.03), respectively, and 4/6 (67%) were mild. One-year post-LT, there was no difference in graft survival (100%), patient survival (97-100%), or the incidence of opportunistic infections.

*Conclusions: Our cohort that received no induction with delayed CNI initiation had a significantly greater improvement in eGFR at three months post-transplant compared to the induction group despite having a higher MELD-Na score and worse baseline eGFR. Although BPAR was higher in the no induction group, one year patient and graft survival were not statistically different. Herein, we report that delayed CNI initiation without induction IS in LTR with renal impairment is safe and could result in significant cost savings.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Zurick T, Bruno D, Kumar D, Winstead R, Song C, Brown A, Sterling S, Yakubu I. Impact of Induction Immunosuppression on Renal Recovery in Adult Liver Transplant Recipients – A Single Center Experience [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/impact-of-induction-immunosuppression-on-renal-recovery-in-adult-liver-transplant-recipients-a-single-center-experience/. Accessed May 17, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences